1. NORSTENT
Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal stent (BMS) (n = 4,509). Clopidogrel was recommended for 9 months after the procedure.
Results
(p = 0.66)
Death or MI at a median of 5 years: 16.6% of the DES group versus 17.1% of the BMS group (p = 0.66)
TLR: 5.3% versus 10.3%, respectively, for DES versus BMS (p < 0.001)
Definite stent thrombosis: 0.8% versus 1.2%, respectively, for DES versus BMS (p = )
17.1
16.6 %
Conclusions
Similar rates of long-term death or MI were observed with DES versus BMS
DES were associated with an approximate 3% absolute reduction in repeat revascularization and a small, but significant reduction in stent thrombosis
DES
BMS
Bønaa KH, et al. N Engl J Med 2016;375: